Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors

NCT05505877 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: BR790+Tislelizumab

Sponsor

Shanghai Gopherwood Biotech Co., Ltd.